RE:RE:Accountability for Low-value DealsGeorgeparros wrote: Hi jd,
Would you say DrDR or John Proffett are out of line? I thought Shadow Lake Group were the expert in valuing a collaboration between xB3 and a licensee.
I think the more the merrier. It's one drug, no exclusivity, and we don't know the royalty rate. We got cash from a private biotech company, probably operating at a loss? Steal imho.
I think getting one million from this Korean company is harder than getting 25 from a BP.
GP
I think it's a good deal. At this point any deal is a good deal. I say let any pharma that wants to, try one drug for no payment, just milestones and royalty. All we need is one success to change the game. Then no more freebies.